PIQ are certainly very good at picking research collaborations to further their pipeline in the Promarker platform. I’m sure we all know someone with Barrett’s Oesophagus & something that affects young people.
The collaboration is over 1 year, and in the big scheme of things in test development, that really isn’t that long (as we know investing in PIQ). It looks like QIMR are quite advanced with their biomarker panel with patents pending in EU, USA, Australia, China & Canada. PIQ will be clinically validating these biomarkers through a simple blood test that has the potential to greatly improve screening for oesophageal adenocarcinoma. PIQ has first option to licence the test in this indication.
The Janssen Ph2 PromarkerD (DKD) collaboration should be getting closer to completion & will be peer reviewed before release.
After a successful Phase 1 with Janssen, they elected to move on to Ph2 to look at the predictive value of PromarkerD in patients treated with Canafliglozin for DKD. Results expected later in QY2020, and there was mention of October/November completion earlier on for this Ph2. (Ref: Investor Presentation August 2020).
In addition to this, the collaboration with Janssen will be investigating whether PromarkerD can predict cardiac outcomes in Diabetics treated with canafliglozin, results expected FY2021. (Ref: Annual Report to Shareholders 2020, p15).
Which makes total sense now why they looked at the CANVAS trial (CKD+CVD) instead of the CREEDENCE trial (CKD) for canafliglozin. The drug is approved for both CKD & CVD in the USA & for DKD in the EU, on top of treating hyperglycaemia. I can see why they have held off with the FDA Approval application for a CDx because things have changed markedly with this class of drugs & research, & now a cardiovascular indication as well as CKD/DKD.
Over the course of PIQs collaboration with Janssen, there now are more priority applications in with the FDA in the SGLT2 class of drugs for CKD & DKD, and a huge market. This drug class has also changed recommendations for Standard of Care in CKD/DKD & Cardiology for treating Diabetics at risk of CVD.
I’ll post the screen shots to these references separately below.
GLTAH
PIQ Price at posting:
59.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)